ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript

Mohamed Zaki: Yes. Thanks, Brian. This is a — first, I would like to see how the efficacy in the combination second line plus looks like and how it compares in the competitive environment. And definitely, we are looking to see how the safety profile is looking like. We’re very pleased that we cleared all those and see that when we get to that point with the two doses that we’re expanding, if the data persists, we’re definitely planning to have a conversation with the regulators about the possibility of a Phase 3 approval there. At that time, we will see what the comparator are and will be. However, there could be investigated best choice, as you should be aware of because they’re multiple agents and many things could be available at that time. But of course, it’s going to be a data-driven approach and the conversation with the agency is going to tell us more about that.

Brian Cheng: Okay. And then maybe a second one for Pepe. Can you give us a better sense on how you define commercial brand profitability this year, is it factoring in only cost of goods sold and selling and marketing expense or is there additional consideration coming from G&A expense as well? Thank you.

Jose Carmona: Yes. Thanks for the question, Brian. So this year, as in long term, we’ll be able to pay for all the direct commercialization effort. That includes all the sales force, MSLs, the A&P that we’re investing in the drug, the IITs that we have been executing. And on top of that, obviously, cost of goods and whatsoever. So it doesn’t — what it doesn’t include is the pipeline. So our LOTIS-5 and 7 trial and corporate G&A. That is not included.

Brian Cheng: Okay, great, thank you.

Operator: Thank you. And I am showing no further questions from our phone lines. And I’d like to turn the conference back over to Ameet Mallik for any closing remarks.

Ameet Mallik: Thank you very much for joining our call today, and thank you for your continued support. We look forward to keeping you updated on our progress. Have a very nice day, everyone. Thank you.

Operator: This concludes today’s conference call. Thank you for your participation, and you may now disconnect. Everyone, have a wonderful day.